Natural non-mutated epitopes from both topIIα and survivin have previously been investigated as targets for therapeutic CRC vaccines in mice [20, 21], and survivin has been investigated as a vaccine target in humans [22, 23]. This evidence concerns the gene TOP2A and colorectal carcinoma.